House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Obstetrics & gynaecology

Preterm labour and birth

NICE · 2022 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

For singleton pregnancies, NICE NG25 links prevention, investigation of membrane rupture and gestation-specific management of threatened or established preterm birth. Its recommendations distinguish suspected labour, diagnosed labour and established labour, and preserve different thresholds for progesterone, cerclage, tocolysis, corticosteroids and fetal neuroprotection.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Preserve the combined versus alternative eligibility criteria

  • Offer a choice of vaginal progesterone or cervical cerclage only when both criteria are present: prior spontaneous birth up to 34+0 weeks or pregnancy loss from 16+0 weeks, and cervical length at most 25 mm on transvaginal scanning at 16+0–24+0 weeks. Make the choice jointly. [1]
  • Consider vaginal progesterone when either qualifying history or a short cervix is present: spontaneous birth up to 34+0 weeks or loss from 16+0 weeks, or cervical length at most 25 mm at 16+0–24+0 weeks. Start progesterone at 16+0–24+0 weeks and continue to at least 34 weeks. [1]
  • Consider prophylactic cerclage for cervical length at most 25 mm at 16+0–24+0 weeks together with previous PPROM or cervical trauma. Document a suture-removal plan whenever prophylactic cerclage is used. [1]
  • Consider emergency cerclage at 16+0–27+6 weeks for a dilated cervix with exposed but unruptured membranes, considering gestation and dilatation with consultant obstetric and paediatric input. Do not offer it with infection, active vaginal bleeding or uterine contractions; explain risks and document removal planning. [1]

Confirm membrane rupture and assess infection appropriately

  • For symptoms of PPROM, use a speculum examination. Visible pooling is sufficient to manage as PPROM without another diagnostic test; absent pooling warrants a vaginal-fluid IGFBP-1 or PAMG-1 test. Do not use nitrazine or perform PPROM diagnostic tests once labour is established. [1]
  • A positive membrane biomarker alone should not dictate care: consider clinical condition, history and gestation, then manage as PPROM or reassess later. With a negative test and no observed fluid, do not give prophylactic antibiotics; explain the low likelihood of PPROM and advise reassessment for further symptoms. [1]
  • For PPROM, offer oral erythromycin 250 mg four times daily for up to 10 days or until established labour, whichever occurs first. If erythromycin is contraindicated or not tolerated, consider oral penicillin for the same maximum duration. Do not use co-amoxiclav for this prophylaxis. [1]
  • Diagnose intrauterine infection in PPROM using clinical assessment together with CRP, white-cell count and fetal heart-rate assessment by CTG. None of these tests alone confirms or excludes infection; observe and consider repeat testing when findings conflict. [1]

Use the gestation-specific diagnostic pathway

  • For symptoms with intact membranes, assess history, observations and the cervix by speculum, using digital examination if needed. Obtain an anticipated fetal-fibronectin swab before digital examination. If clinical assessment suggests preterm labour at 29+6 weeks or earlier, advise treatment through the tocolysis and corticosteroid pathways. [1]
  • At 30+0 weeks or later with suspected preterm labour, consider transvaginal cervical length to assess birth likelihood within 48 hours. A length at most 15 mm means diagnosed preterm labour; above 15 mm, consider alternative diagnoses, discuss home versus hospital care and advise return for persistent or recurrent symptoms. [1]
  • At 30+0 weeks or later, consider fetal fibronectin if indicated cervical-length ultrasound is unavailable or unacceptable. Above 50 ng/ml indicates diagnosed labour; at most 50 ng/ml makes it unlikely. For a negative result, consider alternatives, discuss observation versus home and advise return if symptoms persist or recur. [1]
  • If suspected preterm labour at 30+0 weeks or later cannot be excluded with cervical-length ultrasound or fetal fibronectin, offer treatment as diagnosed labour. Do not combine both tests to diagnose preterm labour. [1]

Match tocolysis and corticosteroids to gestation and circumstances

  • With intact membranes, consider nifedipine at 24+0–25+6 weeks for suspected labour and offer it at 26+0–33+6 weeks for suspected or diagnosed labour. Consider bleeding or infection that may contraindicate stopping labour, corticosteroid benefit, neonatal-care availability and the person’s preference. [1]
  • If nifedipine is contraindicated, offer an oxytocin-receptor antagonist for tocolysis. Do not offer betamimetics. [1]
  • At 22+0–23+6 weeks, discuss corticosteroids individually with the person and multidisciplinary team for suspected or established labour, planned preterm birth or PPROM. Offer at 24+0–33+6 weeks and consider at 34+0–35+6 weeks for suspected, diagnosed or established labour, planned birth or PPROM. [1]
  • Consider one repeat corticosteroid course before 34+0 weeks only when the previous course was more than 7 days earlier and birth risk is very high within 48 hours. Consider fetal-growth effects below 30+0 weeks or with suspected growth restriction; give no more than 2 courses overall. [1]

Use magnesium with the correct timing and toxicity monitoring

  • For established preterm labour or planned birth within 24 hours, discuss IV magnesium neuroprotection individually at 23+0–23+6 weeks, offer it at 24+0–29+6 weeks and consider it at 30+0–33+6 weeks. [1]
  • Give magnesium sulfate as a 4 g IV bolus over 15 minutes followed by 1 g/hour until birth or 24 hours, whichever is sooner. Monitor pulse, blood pressure, respiratory rate and deep-tendon reflexes at least every 4 hours; oliguria or renal failure requires more frequent checks and reducing or stopping magnesium. [1]

Discuss monitoring and mode of birth with their evidence limits

  • In established preterm labour without other risk factors, offer external CTG or intermittent auscultation. Explain the limited evidence that CTG improves outcomes, and involve a senior obstetrician in monitoring decisions at 23+0–25+6 weeks. [1]
  • Do not use fetal blood sampling before 34+0 weeks. A fetal scalp electrode before 34+0 weeks is an exception only when external CTG and auscultation are impossible, senior review has occurred, benefits outweigh risks, and discussed alternatives are unacceptable to the person. [1]
  • Discuss gestation-specific benefits and risks of vaginal and caesarean birth, including the greater likelihood and future implications of a classical uterine incision. Consider caesarean birth for breech presentation in suspected, diagnosed or established preterm labour at 26+0–36+6 weeks. [1]
  • Delay cord clamping for at least 60 seconds unless a specific maternal or fetal condition requires earlier clamping. Position the baby at or below placental level before clamping. Provide early written and spoken information, neonatal-team access and opportunities to discuss resuscitation wishes. [1]

Limitations and use

  • Gestational notation is weeks plus days, not decimal weeks. This summary does not provide complete corticosteroid or tocolytic drug regimens, intrapartum antibiotic protocols, or every fetal monitoring decision. Diabetes-specific corticosteroid management and detailed neonatal care require the linked guidance. Recommendations to discuss, consider and offer are intentionally distinct.
  • This pathway is for singleton pregnancies, not twins or triplets. Confirm local availability of fetal-fibronectin testing; where unavailable, use the stated alternative pathway.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Preterm labour and birth

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
20 November 2015
Publisher’s latest update
10 June 2022
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Preserve the combined versus alternative eligibility criteria
  • Confirm membrane rupture and assess infection appropriately
  • Use the gestation-specific diagnostic pathway
  • Match tocolysis and corticosteroids to gestation and circumstances
  • Use magnesium with the correct timing and toxicity monitoring
  • Discuss monitoring and mode of birth with their evidence limits
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House